For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

IGF-1 LR3

Also known as: Long R3 IGF-1

IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog with a 13-residue N-terminal extension (MFPAMPLSSLFVN) and an Arg-3 substitution. These modifications reduce binding to IGF binding proteins (IGFBPs), extending effective half-life and increasing tissue bioavailability relative to native IGF-1. It is a research/cell-culture reagent and is NOT FDA-approved for any human use. Do not confuse with mecasermin (Increlex), which is recombinant human IGF-1 and IS FDA-approved for severe primary IGF-1 deficiency.

Real-time market data

Pricing for IGF-1 LR3

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$98.63/mg

range $0.00–$430.00/mg

Sellers

54

from $0.00

45-day trend

+17.4%

vs 45-day avg $/mg

47 of 54 sellers have a current price· 34 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for IGF-1 LR3

54 third-party tests across 17 vendors. Each card links to the full report.

All 54 COAs for IGF-1 LR3 →
Measured purity 95.0%–100.0% across 35 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.14 %
Jun 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Peptide Plugs· batch 140-01-DK

Aggregated · 3rd-party listing
99.16 %
May 2026
ILS Labs Strong

For

IGF-1 LR3

by Ion Peptide· batch IGF1-052026

Aggregated · 3rd-party listing
99.22 %
May 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Peptide Supply Co.· batch IG105192026

Aggregated · 3rd-party listing
99.95 %
Apr 2026
Biogenica Labs · HPLC

For

IGF-1 LR3

by Amino Club· batch IGF0001

Aggregated · 3rd-party listing
99.60 %
Mar 2026
Analytical Formulations, Inc.

For

IGF-1 LR3

by Ion Peptide· batch IGF1-03102026

Aggregated · 3rd-party listing
99.16 %
Mar 2026
Freedom Diagnostics Moderate · HPLC

For

IGF-1 LR3

by Peptide Supply Co.· batch GLR31031026

Aggregated · 3rd-party listing
99.53 %
Mar 2026
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Real Peptides

✓ Vendor-published
98.89 %
Feb 2026
Vanguard Laboratory Strong

For

IGF-1 LR3

by Mile High Compounds· batch IGF-001-MH-02

COA on file
Aggregated · 3rd-party listing
98.87 %
Feb 2026
Vanguard Laboratory Strong · HPLC

For

IGF-1 LR3

by Mile High Compounds· batch IGF-001-MH-02

Aggregated · 3rd-party listing
99.80 %
Jan 2026
Bioviridian Moderate

For

IGF-LR3

by Ion Peptide· batch IGFL-010226

Aggregated · 3rd-party listing
99.06 %
Jan 2026
Janoshik Analytical Limited · HPLC

For

IGF-1 LR3

by Skye Peptides· batch IGF25-1-003

Aggregated · 3rd-party listing
95.28 %
Dec 2025
Chromate Moderate

For

IGF-1 LR3

by Orbitrex Peptides

Aggregated · 3rd-party listing
99.08 %
Dec 2025
Freedom Diagnostics Moderate · HPLC

For

IGF-LR3

by Simple Peptide· batch IGFR12172025-J

✓ Vendor-published
95.04 %
Nov 2025
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Ion Peptide· batch IL1-1025

COA on file
Aggregated · 3rd-party listing
96.27 %
Nov 2025
Janoshik Analytical Limited · HPLC

For

IGF-1 LR3

by ZLZ peptides· batch cmojgromn00539grxzzwqeri4

Aggregated · 3rd-party listing
95.04 %
Nov 2025
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Ion Peptide· batch IL-L-1025

Aggregated · 3rd-party listing
99.45 %
Nov 2025
Janoshik Analytical Limited

For

IGF-1 LR3

by Cernum Biosciences

Aggregated · 3rd-party listing
96.47 %
Oct 2025
Freedom Diagnostics Moderate

For

IGF-1 LR3

by Ion Peptide· batch IL-1025

Aggregated · 3rd-party listing
99.79 %
Oct 2025
Janoshik Analytical Limited

For

IGF-1 LR3

by Eternal Peptides· batch EP-250526-IG1

Aggregated · 3rd-party listing
99.64 %
Oct 2025
Vanguard Laboratory Strong

For

IGF-LR3

by Peptidology· batch 1665

Aggregated · 3rd-party listing
97.45 %
Sep 2025
Freedom Diagnostics Moderate · HPLC

For

IGF-LR3

by Simple Peptide· batch IGLR09222025-J

Aggregated · 3rd-party listing
95.76 %
Sep 2025
Freedom Diagnostics Moderate

For

IGF-LR3

by Kimera Chems

Aggregated · 3rd-party listing
99.36 %
Sep 2025
Janoshik Analytical Limited · HPLC

For

IGF-1 LR3

by Profound Aminos· batch cmojb86a401h8kirxvxbas7o4

Aggregated · 3rd-party listing
99.79 %
Aug 2025
Janoshik Analytical Limited · HPLC

For

IGF-1 LR3

by Verified Peptides· batch 09-25-0301C

Research depth

12 citations indexed for IGF-1 LR3

All research on IGF-1 LR3 →

Study · 2026

IGF-1 Increases Collagen Deposition by Dermal Fibroblasts: Applications for Tissue Engineering

Tissue engineering using the self-assembly approach represents a promising technology. However, age-related reductions in extracellular matrix deposition by stromal cells limit the mechanical robustness of reconstructed tissues what can be critical for midurethral sling reconstruction.

review · 2026

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration

Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.

Study · 2026

Intact Proteoform Analysis by Capillary Electrophoresis-Mass Spectrometry. Are We There Yet?

Mass spectrometry (MS)-based top-down proteomics (TDP) has emerged as a powerful tool for characterizing proteoforms to advance both fundamental and translational research. TDP requires high-efficiency liquid-phase separation, high-resolution MS, and tandem MS.

review · 2026

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.

animal · 2025

Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration

Peripheral nerve injuries lead to significant functional deficits, with no treatment achieving complete recovery. Autologous nerve grafting remains the gold standard, but it is limited by donor site morbidity. Artificial nerve conduits have been developed but have not matched the outcomes of autologous grafts.

animal · 2025

IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep

Insulin-like growth factor-1 (IGF-1) and insulin are important fetal anabolic hormones.